Skip to main content

Table 1 Gene expression profiles of prostate cancer used for integrative analysis#

From: Integrative analysis reveals disease-associated genes and biomarkers for prostate cancer progression

No. Exp.

Platform

No. Probes

Samples Series

No. Samples of prostate cancer stages

References

    

NAP

BN

PCA

MET

 
    

(I)

(II)

(III)

(IV)

 
    

Early phase

Middle phase

Late phase

 

Exp-1

Affymetrix HG-U133P2

GPL570

54,675

GSE3325

0

6

7

6

[76]

Exp-2

cDNAChinnaiyan Human 20K Hs6

GPL2013

20,000

GES6099

0

15

32

20

[77]

Exp-3

Agilent-014850 4x44K G4112F

GPL4133

45,220

GSE27616

0

2

5

4

[78]

Exp-4

Affymetrix HG-U133A

GPL96

22,283

GSE3868

2

0

22

0

[79]

Exp-5

Affymetrix HGU95A

-

12,626

-

9

0

25

0

[80]

Exp-6

Affymetrix HG-U133P2

GPL570

54,675

GSE17951

0

45

109

0

[81, 82]

Exp-7

Agilent-014850 4x44K G4112F

GPL6480

 

GSE28204

0

4

4

0

[83]

Exp-8

Affymetrix HG_U95Av2

GPL8300

12,625

GSE6919

18

0

65

25

[84, 85]

  1. #Abbreviations: NAP: normal prostate samples, BN: benign samples, PCA: primary prostate cancer samples, MET: metastatic prostate cancer samples